Advances in Clinical and Experimental Medicine

Adv Clin Exp Med
Impact Factor (IF) – 1.514
Index Copernicus (ICV 2018) – 157.72
MNiSW – 40
Average rejection rate – 84.38%
ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download PDF

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 3, March, p. 407–413

doi: 10.17219/acem/90767

Publication type: review article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Creative Commons BY-NC-ND 3.0 Open Access

Treatment of ovarian endometrial cysts in the context of recurrence and fertility

Izabela Nowak-Psiorz1,A,B,C,D,F, Sylwester M. Ciećwież1,A,B,C,D,F, Agnieszka Brodowska1,A,B,D,F, Andrzej Starczewski1,A,B,D,F

1 Department of Gynecology, Endocrinology and Gynecologic Oncology, Pomeranian Medical University, Szczecin, Poland

Abstract

An approach to ovarian endometrial cysts has changed considerably during recent years, especially in regard to treatment of recurrent endometriosis, fertility sparing and infertility management. Surgical treatment is the primary therapeutic option. The most efficient types of treatment are radical procedures involving adhesiolysis, removal of the cyst along with its capsule and any remaining endometriotic foci. However, small asymptomatic cysts should not be treated surgically, especially in patients older than 35 years. Surgical treatment can be considered in infertile women and those who failed to get pregnant despite 1–1.5 years of trials, as well as in cases in which in vitro fertilization is not an option. Also large cysts, with more than 4 cm in diameter, should be treated surgically due to the risk of their rupture or torsion. The most efficient preventive measure for recurrent ovarian endometriosis is unilateral oophorectomy with sparing the contralateral ovary. Such a procedure should be considered in women who are no longer interested in childbearing or present with another endometriotic cyst in the same ovary. The role of pharmacotherapy is fairly limited; it should be considered in patients in whom diffuse endometriosis is associated with pain. Therapeutic agents from the following groups can be used: estrogen-progestin preparation, gestagens, including progesteronereleasing intrauterine systems and gonadotropin-releasing hormone agonists. Women with infertility should get pregnant as soon as possible, and in patients who failed to get pregnant and/or are older than 35 years, in vitro fertilization should be the treatment of choice.

Key words

endometriosis, pharmacotherapy, surgical treatment, endometrioma

References (60)

  1. Leyland N, Casper R, Laberge P, Singh SS; SOGC. Endometriosis: Diagnosis and management. J Obstet Gynaecol Can. 2010;32(7 Suppl 2):S1–S32.
  2. Jiang QY, Wu RJ. Growth mechanisms of endometriotic cells in implanted places: A review. Gynecol Endocrinol. 2012;28(7):562–567.
  3. Yang CW, Chang CY, Lai MT, et al. Genetic variations of MUC17 are associated with endometriosis development and related infertility. BMC Med Genet. 2015;16:015–0209.
  4. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014;19.
  5. Sayasneh A, Wynants L, Preisler J, et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. Br J Cancer. 2013;108(12):2448–2454.
  6. Van Calster B, Van Hoorde K, Froyman W, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts Views Vis Obgyn. 2015;7(1):32–41.
  7. Szubert M, Suzin J, Wierzbowski T, Kowalczyk-Amico K. CA-125 concentration in serum and peritoneal fluid in patients with endometriosis – preliminary results. Arch Med Sci. 2012;8(3):504–508.
  8. Dunselman GA, Vermeulen N, Becker C, et al; European Society of Human Reproduction and Embryology. ESHRE guideline: Management of women with endometriosis. Hum Reprod. 2014;29(3):400–412.
  9. Schliep KC, Mumford SL, Peterson CM, et al. Pain typology and incident endometriosis. Hum Reprod. 2015;30(10):2427–2438.
  10. Uncu G, Kasapoglu I, Ozerkan K, Seyhan A, Oral Yilmaztepe A, Ata B. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod. 2013;28(8):2140–2145.
  11. Ofer A, Shulman LP, Singh SS. Improving the Treatment and Management of Endometriosis: Improving the treatment and management of endometriosis: An overview of current and novel approaches. Am J Obstet Gynecol. 2015;19:02543–02540.
  12. Coccia ME, Rizzello F, Mariani G, Bulletti C, Palagiano A, Scarselli G. Ovarian surgery for bilateral endometriomas influences age at menopause. Hum Reprod. 2011;26(11):3000–3007.
  13. Tsoumpou I, Kyrgiou M, Gelbaya TA, Nardo LG. The effect of surgical treatment for endometrioma on in vitro fertilization outcomes: A systematic review and meta-analysis. Fertil Steril. 2009;92(1):75–87.
  14. Saleh A, Tulandi T. Reoperation after laparoscopic treatment of ovarian endometriomas by excision and by fenestration. Fertil Steril. 1999;72(2):322–324.
  15. Golfier F, Sabra M. Surgical management of endometriosis [in French]. J Gynecol Obstet Biol Reprod. 2007;36(2):162–172.
  16. Fayez JA, Vogel MF. Comparison of different treatment methods of endometriomas by laparoscopy. Obstet Gynecol. 1991;78(4):660–665.
  17. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–1799.
  18. Hart RJ, Hickey M, Maouris P, et al. Excisional surgery versus ablative surgery for ovarian endometriomata. Cochrane Database Syst Rev. 2008;16(2):CD004992.
  19. Alborzi S, Momtahan M, Parsanezhad ME, Dehbashi S, Zolghadri J, Alborzi S. A prospective, randomized study comparing laparoscopic ovarian cystectomy versus fenestration and coagulation in patients with endometriomas. Fertil Steril. 2004;82(6):1633–1637.
  20. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: Frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20(2):133–139.
  21. Moini A, Arabipoor A, Ashrafinia N. Risk factors for recurrence rate of ovarian endometriomas following a laparoscopic cystectomy. Minerva Med. 2014;105(4):295–301.
  22. Ouchi N, Akira S, Mine K, Ichikawa M, Takeshita T. Recurrence of ovarian endometrioma after laparoscopic excision: Risk factors and prevention. J Obstet Gynaecol Res. 2014;40(1):230–236.
  23. Li HJ, Leng JH, Lang JH, et al. Correlative factors analysis of recurrence of endometriosis after conservative surgery [in Chinese]. Zhonghua Fu Chan Ke Za Zhi. 2005;40(1):13–16.
  24. Porpora MG, Pallante D, Ferro A, Crisafi B, Bellati F, Benedetti Panici P. Pain and ovarian endometrioma recurrence after laparoscopic treatment of endometriosis: A long-term prospective study. Fertil Steril. 2010;93(3):716–721.
  25. Liu X, Yuan L, Shen F, Zhu Z, Jiang H, Guo SW. Patterns of and risk factors for recurrence in women with ovarian endometriomas. Obstet Gynecol. 2007;109(6):1411–1420.
  26. Koga K, Takemura Y, Osuga Y, et al. Recurrence of ovarian endometrioma after laparoscopic excision. Hum Reprod. 2006;21(8):2171–2174.
  27. Yun BH, Jeon YE, Chon SJ, et al. The prognostic value of individual adhesion scores from the revised American Fertility Society Classification System for Recurrent Endometriosis. Yonsei Med J. 2015;56(4):1079–1086.
  28. Ghezzi F, Beretta P, Franchi M, Parissis M, Bolis P, Recurrence of ovarian endometriosis and anatomical location of the primary lesion. ­Fertil Steril. 2001;75(1):136–140.
  29. Guzel AI, Topcu HO, Ekilinc S, et al. Recurrence factors in women underwent laparoscopic surgery for endometrioma. Minerva Chir. 2014;69(5):277–282.
  30. Parazzini F, Bertulessi C, Pasini A, et al; Gruppo Italiano di Studio Endometriosi.. Determinants of short term recurrence rate of endometriosis. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):216–219.
  31. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–461.
  32. Luisi S, Galleri L, Marini F, Ambrosini G, Brandi ML, Petraglia F. Estrogen receptor gene polymorphisms are associated with recurrence of endometriosis. Fertil Steril. 2006;85(3):764–766.
  33. Yuan L, Shen F, Lu Y, Liu X, Guo SW. Cyclooxygenase-2 overexpression in ovarian endometriomas is associated with higher risk of recurrence. Fertil Steril. 2009;91(4 Suppl):1303–1306.
  34. Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril. 1995;64(5):898–902.
  35. Chalermchockchareonkit A, Tekasakul P, Chaisilwattana P, Sirimai K, Wahab N. Laparoscopic hysterectomy versus abdominal hysterectomy for severe pelvic endometriosis. Int J Gynaecol Obstet. 2012;116(2):109–111.
  36. Muzii L, Marana R, Caruana P, Mancuso S. The impact of preoperative gonadotropin-releasing hormone agonist treatment on laparoscopic exci-sion of ovarian endometriotic cysts. Fertil Steril. 1996;65(6):1235–1237.
  37. Blumenfeld Z. Hormonal suppressive therapy for endometriosis may not improve patient health. Fertil Steril. 2004;81(3):487–492.
  38. Selak V, Farquhar C, Prentice A, Singla A. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst Rev. 2007;17(4):CD000068..
  39. Seracchioli R, Mabrouk M, Frasca C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: A randomized controlled trial. Fertil Steril. 2010;93(1):52–56.
  40. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: An update for clinicians. Hum Reprod Update. 2006;12(2):179–189.
  41. Vercellini P, Somigliana E, Daguati R, Vigano P, Meroni F, Crosignani PG. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol. 2008;198(5):504.e1–5.
  42. Zorbas KA, Economopoulos KP, Vlahos NF. Continuous versus cyclic oral contraceptives for the treatment of endometriosis: A systematic review. Arch Gynecol Obstet. 2015;292(1):37–43.
  43. Cucinella G, Granese R, Calagna G, et al. Oral contraceptives in the prevention of endometrioma recurrence: Do the different progestins used make a difference? Arch Gynecol Obstet. 2013;288(4):821–827.
  44. Schindler AE. Dienogest in long-term treatment of endometriosis. Int J Womens Health. 2011;3:175–184.
  45. Muzii L, Marana R, Caruana P, Catalano GF, Margutti F, Panici PB. Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: A prospective, randomized trial. Am J Obstet Gynecol. 2000;183(3):588–592.
  46. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015;104(4):793–801.
  47. Yanase T, Ishida M, Nishijima S, et al. Outcomes of treatment with cyclic administration of dienogest after ovarian endometriotic cystectomy. Gynecol Endocrinol. 2015;31(8):643–646.
  48. Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand. 2014;93(1):38–44.
  49. Morelli M, Sacchinelli A, Venturella R, Mocciaro R, Zullo F. Postoperative administration of dienogest plus estradiol versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gynaecol. 2013;39(5):985–990.
  50. Jee BC, Lee JY, Suh CS, Kim SH, Choi YM, Moon SY. Impact of GnRH agonist treatment on recurrence of ovarian endometriomas after con-servative laparoscopic surgery. Fertil Steril. 2009;91(1):40–45.
  51. Alborzi S, Hamedi B, Omidvar A, Dehbashi S, Alborzi S, Alborzi M. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet. 2011;284(1):105–110.
  52. Georgievska J, Sapunov S, Cekovska S, Vasilevska K. Effect of two laparoscopic techniques for treatment of ovarian endometrioma on ovarian reserve. Med Arch. 2015;69(2):88–90.
  53. Kitajima M, Defrere S, Dolmans MM, et al. Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis. Fertil Steril. 2011;96(3):685–691.
  54. Seyhan A, Ata B, Uncu G. The impact of endometriosis and its treatment on ovarian reserve. Semin Reprod Med. 2015;33(6):422–428.
  55. Biacchiardi CP, Piane LD, Camanni M, et al. Laparoscopic stripping of endometriomas negatively affects ovarian follicular reserve even if performed by experienced surgeons. Reprod Biomed Online. 2011;23(6):740–746.
  56. Hwu YM, Wu FS, Li SH, Sun FJ, Lin MH, Lee RK. The impact of endometrioma and laparoscopic cystectomy on serum anti-Mullerian hormone levels. Reprod Biol Endocrinol. 2011;9:1477–7827.
  57. Urman B, Alper E, Yakin K, et al. Removal of unilateral endometriomas is associated with immediate and sustained reduction in ovarian reserve. Reprod Biomed Online. 2013;27(2):212–216.
  58. Tang Y, Chen SL, Chen X, et al. Ovarian damage after laparoscopic endometrioma excision might be related to the size of cyst. Fertil Steril. 2013;100(2):464–469.
  59. Kuczyński W, Kurzawa R, Oszukowski P; Polish Gynecological Society and Polish Society for Reproductive Medicine. Polish Gynecological Society and Polish Society for Reproductive Medicine recommendations for the diagnosis and treatment of infertility [in Polish]. Ginekol Pol. 2012;83(2):149–154.
  60. National Institute for Health and Clinical Excellence. Fertility problems: Assessment and treatment. Clinical guideline. National Institute for Health and Clinical Excellence. http://niceorguk/guidance/cg156. Accessed February 5, 2017.